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Is immunosenescence an intrinsic ageing process leading to dysregulation of immunity or an adaptive response of
the individual to pathogen exposure? Age-associated differences in bone marrow immune cell output and thymic
involution suggest the former. Accepted hallmarks of immunosenescence (decreased numbers and percentages of
peripheral naïve T cells, especially CD8 + cells, and accumulations of memory T cells, especially late-stage
differentiated CD8+ cells) suggest the latter, viewed as the result of depletion of the reservoir of naïve cells over
time by contact with pathogens and their conversion to memory cells, the basis of adaptive immunity. Thymic
involution beginning early in life limits the generation of naive cells such that the adult is believed to rely to a
great extent on the naïve cell pool produced mostly before puberty. Thus, these hallmarks of immunosenescence
would be markedly affected by the history of the individual´s exposure to pathogens. It would be predicted that in
modern industrialized populations, the cumulative effects of antigenic “stressors” would be lower than in less
hygienic societies, whereas intrinsic processes might be more similar in different populations. Identifying such
stressors and taking steps to nullify their impact could therefore result in delayed immunosenescence and
contribute significantly to improving public health. Here, I discuss some of the available data bearing on this
prediction.How can we define and measure
“immunosenescence”?
To answer any questions on immunity and ageing, we
clearly need to have a means to measure immunosenes-
cence. At the moment, we only have rather unrefined
biomarkers which we believe may reflect detrimental
effects of age. Traditionally, cross-sectional studies in
industrialized countries have almost unanimously docu-
mented lower numbers and/or proportions of peripheral
blood naïve CD8+ T cells in the elderly, whereas age-
effects on CD4+ T cells have been harder to pin down.
Reciprocally, memory CD8+T cells are more numerous
in the elderly, again with lesser and more discordant
effects reported for CD4+T cells [1–3]. It has been the
assumption that the greater susceptibility of the elderly
than the young to novel infections reflects this lesser
availability of naïve cells poised to recognize new anti-
gens. To the best of my knowledge, however, this assump-
tion has never been experimentally tested in humans.Correspondence: graham.pawelec@uni-uebingen.de
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reproduction in any medium, provided the orBased on a series of prospective cohort studies of the
very elderly in Sweden, the concept of an “immune risk
profile” (IRP), however, has gained traction over the
past decade. The IRP was found to be present in around
15% of 85-year-olds in the OCTO/NONA studies at
baseline [4,5]. Follow-up of 2-, 4- and 6-year mortality
revealed significantly higher all-cause mortality in the
IRP group than in the majority of very elderly. The IRP
was characterized by a relative deficit in the numbers
and proportions of B cells, and an accumulation of CD8+
memory T cells tipping the CD4:CD8 ratio to less than
unity (in contrast to the majority of elderly where the
CD4:CD8 ratio increases rather than decreasing). This
accumulation of late-stage differentiated cells (double-
negative for the costimulatory receptors CD27 and
CD28) was responsible for the poor T cell proliferative
responses to mitogens which was characteristic of the
cluster of parameters constituting the IRP, as the major-
ity of these cells were later found also to express KLRG-
1 and CD57 (ie., double-positive for negative regulatory
coreceptors). This phenotype, or more commonly sim-
ply CD8 +CD28-negative, is often taken to mark senes-
cent cells; I would argue strongly against this, althoughThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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would indicate designating them only as “late-stage dif-
ferentiated”. It should be noted here that the numbers
and proportions of CD8+ naïve cells were NOT part of
the IRP, being greatly reduced in both groups. Addition-
ally, neither naive or memory CD4+ T cells featured in
these studies as informative for all-cause mortality [4,5].
The final parameter of the original IRP was, remark-
ably, Cytomegalovirus seropositivity. Although this per-
sistent herpesvirus infected 85 % of the whole elderly
population, every individual in the IRP group was a car-
rier. Thus, CMV-seropositivity was a part of the IRP;
however, most CMV-infected people were nonetheless
not in the IRP, already clearly indicating that CMV is a
contributing but not controlling factor [6–9]. Studies of
2-, 4- and 6-year survival in these cohorts also revealed
a second set of parameters, independent of the IRP, but
at least additive with the IRP, which associated with
mortality. These factors were higher levels of the pro-
inflammatory cytokine IL 6, associated with frailty and
mortality in countless studies, together with measures of
cognitive impairment. Because some of the literature
refers to the “IRP” as also including IL 6, I stress here
that the only studies documenting the original IRP did
NOT include IL 6. Thus survival of people with lower IL
6 and not in the IRP was better than those with the IRP
alone, or high IL 6 alone, and much better than people
in the IRP who also had high IL 6 [4,5]. The literature
also includes many papers referring to the presence or
absence of the IRP in different populations and situa-
tions. Again, I emphasize that the only studies showing
the IRP to be informative for mortality are the Swedish
OCTO/NONA studies. Whether this is also true of
other populations has not been tested. Moreover, we do
not know at which calendar age the IRP may become
predictive of mortality; very preliminary data suggests
possibly 60 years of age [10]. At much older ages, the
IRP is again not predictive, in that no subjects surviving
long enough are found to be in the IRP category,
presumably due to selection of those who were [11].
Consistent with this, we have recently completed a
small-scale study of subjects in the Leiden 85-Plus study,
which as the name suggests also started from a baseline
of 85 [12]. Here, we analyzed subjects at the age of 89
and found that only one was in the IRP. Thus, in the
highly selected very elderly population, one would not
necessarily expect to find anyone still in the risk group.
Fascinatingly, in the Leiden 85-Plus study, we found that
a lower proportion of naïve CD8+ T cells and a higher
proportion of some CD8+ memory cell phenotypes was
associated with longer survival on 8-year follow-up [12].
Clearly, greater naïve cell capacity under these condi-
tions was not associated with favourable outcome. We
interpret these data to suggest that in a very elderlypopulation presumably not exposed to many new patho-
gens, it is more important to maintain good memory
responses rather than use reserves to meet new chal-
lenges that may never come. The finding that longer
survival was also associated with in unopposed pro-
inflammatory responsiveness to CMV antigens in vitro
[12] underlines the nature of the memory responses that
we propose are essential to maintain in old age. Thus,
these considerations emphasize that immune parameters
associated with survival maybe very different in different
populations at different ages. This makes it unlikely that
general “one size fits all” biomarkers of immune ageing
(or any other parameter for that matter) will be identi-
fied. A consensus view would be that low naïve cells,
high memory cells and high pro-inflammatory states
would mitigate against survival. However, it is clear that
in certain cases, such as the example of the Leiden 85-
Plus described above, the exact opposite seems to be
true. Other exceptional populations, such as centenar-
ians, may also need to be considered separately [13–15].
Genetic variables determining longevity?
Of the many variables potentially influencing longevity
and biomarkers of ageing, the genetic background cer-
tainly represents a likely suspect. Huge amounts of
resources have been and are being expended in search-
ing for genetic and epigenetic influences on human
longevity. Relatively little exploration of immune para-
meters is so far available in this respect, but data emer-
ging from a study of familial longevity may shed some
light on this matter. The Leiden Longevity Study (LLS),
in which the 40-80-year-old subjects, representing 0.5 %
of the general population, enjoy a 30 % decreased stan-
dardized mortality rate, is a very valuable resource in
this respect. It seems that the potentially long-lived off-
spring in the LLS do not show the characteristically
decreased proportions of CD8+ naïve cells, nor the
accumulations of CD8+ late memory cells [16]. A re-
markable finding in these individuals was that even if
they were infected with CMV, their naïve cells were not
“used up”, in contrast to the normal population. It has
become very clear since the first reports of the impact of
CMV on immune parameters [17,18] that it is the fact of
infection with this persistent virus that is to a large
degree responsible for the shifts in the proportions of
CD8+ naïve and memory cells. Thus, in cross-sectional
studies of people of different ages, those who are CMV-
negative do not show loss of naïve cells at all, or to
nothing like to the same degree [16,19]. The fact that
CMV actually causes these shifts is made highly likely by
findings from allograft transplantation where a CMV+
organ causes infection of a CMV-negative recipient,
with rapid loss of naïve cells and accumulation of mem-
ory cells [20]. Hence, in people genetically predisposed
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amount of immune resources otherwise taken up with
CMV immunosurveillance throughout life may provide
an advantage in itself. This in turn would suggest that
people in the general population who remain CMV-
negative might also have a survival advantage. There is
indeed some evidence for this from several studies, in-
cluding the large NHANES survey of 14,000 adults over
10 years [21,22].
Does immunosenescence occur earlier in life in
developing countries?
Most studies attempting to assess immunosenescence or
biomarkers of immune ageing have focused on a single
population, mostly “WEIRD” (ie Western, educated,
industrialized, rich, democratic). These are not necessar-
ily representative of the majority off the world´s popula-
tion. There will not only be differences in genetics, the
effects of which may be wide-ranging, as described
above for the LLS, but also in societal and psychological
factors, and perhaps most importantly in nutritional
status and access to health care. One very striking differ-
ence is also that fact that in the “wild-type” situation, all
humans are infected with CMV from the age of ca.
2 months on, when they no longer receive only anti-CMV
antibody in the mother´s milk, but also the infectious
virus that has reactivated in the meantime. CMV-
negativity is an artifact of civilization, hygiene and
decreased breast feeding. Hence, in our pilot study of
young and old men in rural Pakistan, all the young were
already CMV-positive [23]. As ”old” is viewed as >50 years
in this society, we sought to establish whether age-
associated differences in immune phenotypes that we
and others had established in older European and US
populations were similar in Pakistanis, and whether they
manifested earlier in the latter. We concluded that there
were two major differences between the Pakistani popu-
lation and the historical controls of WEIRD subjects.
One was that we did indeed see age-associated differ-
ences in CD8+ T cells earlier in the Pakistanis, and the
other was that we saw for the first time in a healthy
population that not only the CD8+ subset but also the
CD4 +T cells were affected. This we had otherwise only
seen in pathological European populations, eg. those
with Alzheimer´s [24]. We interpret this to mean that
the level of “antigenic stress” in the Pakistani popula-
tion, old a 50, could indeed be leading to “premature
immunosenescence”.
Conclusions
As far as we know from animal studies, bone-marrow
output of immune cells is affected by age, but varies
greatly dependent on genetic background. The general
finding, though, is that output of myeloid cells increasesand B and T cell progenitors decreases. Whether this is
an intrinsic process reflected in the decreased DNA re-
pair capacity of the compensatorily increased cycling
stem cells is not understood. Why the thymus involutes
as part of a developmental not senescing process is also
not understood. However, against this backdrop of
altered immune cell production, it seems safe to argue
that processes directly responsible for immunosenes-
cence are to a great extent determined by that individ-
ual´s history of pathogen exposure, and in humans,
particularly to infection with CMV. There is therefore
also an argument for medical intervention to offset the
impact of chronic antigenic stress on the immune sys-
tem, which in developing countries would certainly in-
clude CMV, which infects essentially the entire
population. In industrialized countries, where CMV in-
fection rates are probably still decreasing, different, so-
far unidentified pathogens in CMV-negative individuals
may need to be targeted [25].
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